Matching slides 303,780
Current window 202,921-202,950
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

202,921-202,950 of 303,780

filter-aware
26
Reservoir | Investor Presentation Deck | 35 slidesReservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations Beat · Financials1 hit
27
Includes assumptions regarding annual reinvestment strategy.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations Beat · Financials1 hit
28
Reservoir | Investor Presentation Deck | 35 slidesReservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
29
The slide uses a background image of a person, likely a musician, to set the industry context.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
30
The slide uses a background image of two people (likely musicians) and a blue overlay box for the financial metrics.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
31
The slide highlights the cost structure differences between publishing and recorded music, leading to a concluding statement about operating leverage.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
32
Includes a footnote regarding non-cash stock-based compensation.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
33
Note at bottom: Advances moved from Operating to Investing cash flows for illustrative purposes.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
34
The slide includes a background image of a person, likely a stylistic choice for the deck.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
35
Reservoir | Investor Presentation Deck | 35 slidesReservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations 1 hit
01
Slide 1
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
02
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
03
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
04
The slide highlights the strategic advantage of IMVT-1402 building upon existing clinical validation of IgG lowering.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
05
The slide uses a grid layout to categorize medical indications by therapeutic area (Neurology, Hematology, Endocrinology, Rheumatology, Renal, Dermatology).Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
06
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
07
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
08
The slide is partially obscured by a grey overlay, but the primary value proposition is clear.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
11
The slide uses molecular ribbon diagrams to illustrate binding site interference.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
12
Includes financial runway disclosure in the footer.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
13
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
14
The slide uses a comparative layout to differentiate two products in the company's pipeline.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
15
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
16
The slide is mostly obscured by a grey overlay, but the title clearly indicates a strategic roadmap or development plan.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
17
The table uses 'X' marks to indicate feature presence and specific clinical trial/dosing status for the Immunovant franchise.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
18
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
19
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
21
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
01
Slide 1
Includes exhibit number and presenter credentials.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
02
Page number 2 in the top right corner.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit